Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

@article{Davies2007CosteffectivenessOF,
  title={Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.},
  author={Linda M. Davies and S. Lewis and P B Jones and Thomas R. E. Barnes and Fiona Gaughran and Karen P Hayhurst and Alison Markwick and Helen Lloyd},
  journal={The British journal of psychiatry : the journal of mental science},
  year={2007},
  volume={191},
  pages={
          14-22
        }
}
  • L. Davies, S. Lewis, +5 authors H. Lloyd
  • Published 1 July 2007
  • Medicine, Psychology
  • The British journal of psychiatry : the journal of mental science
BACKGROUND There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. AIMS To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia. METHOD Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in… 
View on PubMed
cambridge.org
109 Citations
Highly Influential Citations
3
Background Citations
14
Methods Citations
5
Results Citations
3

Figures, Tables, and Topics from this paper

109 Citations

Citation Type

Citation Type

Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
  • T. Park, K. Kuntz
  • Medicine, Psychology
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2014
Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
TLDR
Policy approaches for containing drug costs are available and could improve cost-effectiveness by encouraging that second-generation antipsychotics be prescribed more selectively, such as only when clearly indicated, but excessively restrictive approaches could unintentionally reduce access to beneficial treatments.
Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
TLDR
Policy approaches for containing drug costs are available and could improve cost-effectiveness by encouraging that second-generation antipsychotics be prescribed more selectively, such as only when clearly indicated, but excessively restrictive approaches could unintentionally reduce access to beneficial treatments.
Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia
TLDR
Effectiveness studies have confirmed the high incidence of adverse metabolic effects with clozapine, olanzapine and (with less certainty) quetiapine but the ZODIAC study found no excess cardiovascular events or deaths for olanZapine compared with ziprasidone.
Developing a policy for second-generation antipsychotic drugs.
TLDR
Stepped therapy, allowing exceptions with prior authorization and giving preference to generic drugs with low risk of both neurologic and metabolic side effects, could increase the cost-effectiveness and safety of antipsychotic drugs.
Antipsychotics and Schizophrenia: From Efficacy and Effectiveness to Clinical Decision-Making
TLDR
Past efficacy trials have strongly supported the position that SGAs are superior to FGAs in the treatment of schizophrenia and in side effect profile, and two large independent effectiveness trials have offered a strong challenge to these claims.
Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial
Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
TLDR
Olanzapine may be a cost-effective therapeutic option for patients with schizophrenia and is predicted in this model to result in better clinical outcomes and lower total direct health care costs compared to generic risperidone, quetiapine, ziprasid one, and aripiprazole.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
TLDR
In people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across 1 year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs.
Service use and costs of treating schizophrenia with atypical antipsychotics.
TLDR
Clozapine was reserved for more severe forms of schizophrenia, but its cost impact was relatively low, and risperidone, as prescribed in ordinary practice, may be more cost-effective than olanzapine.
Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia
TLDR
The study results demonstrate that risperidone is a dominant therapy in this baseline analysis since it is associated with the lowest overall cost and highest number of quality-adjusted life-years (QALYs).
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
TLDR
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
TLDR
There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotic drugs.
Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic
An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics.
Depot antipsychotic preparations in schizophrenia: the state of the economic evidence
TLDR
A systematic review of the international literature in an attempt to find, appraise and summarize the economic evaluative evidence for depot conventional antipsychotic treatment for schizophrenia suggests that depot treatment may lower costs and improve cost-effectiveness.
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
TLDR
Olanzapine does not demonstrate advantages compared with haloperidol (in combination with prophylactic benztropine) in compliance, symptoms, extrapyramidal symptoms, or overall quality of life, and its benefits in reducing akathisia and improving cognition must be balanced with the problems of weight gain and higher cost.
...
1
2
3
4
5
...